Key result
Sugammadex significantly shortened recovery time to a TOF ratio ≥90% compared to neostigmine (MD -15.40; 95% CI -26.64 to -4.15; p=0.0073) and reduced the risk of postoperative residual curarization.
Why the study?
Although sugammadex reverses neuromuscular blockade in patients with obesity undergoing metabolic and bariatric surgery, its effects on systemic complications remain unclear.
Does sugammadex reduce recovery time and complications compared to neostigmine in patients with obesity undergoing metabolic and bariatric surgery?
Population
633 patients with obesity undergoing metabolic and bariatric surgery across nine studies
Comparison
Sugammadex vs neostigmine
Design
Systematic review and meta-analysis with trial sequential analysis
Authors
Loading...
Supports sugammadex preference in bariatric surgery for faster reversal and lower residual curarization risk; confirms meta-analytic superiority over neostigmine in obesity.
Systematic Review (n=633)
Does sugammadex reduce recovery time and complications compared to neostigmine in patients with obesity undergoing metabolic and bariatric surgery?
Mean Difference: -15.4 (95% CI -26.64–-4.15)
p-value: p=0.0073
Sugammadex provides faster and more reliable reversal of neuromuscular blockade with a lower risk of postoperative residual curarization compared to neostigmine in bariatric surgery patients.
Wang et al. (2024) conducted a systematic review in Obesity undergoing metabolic and bariatric surgery (n=633). Sugammadex vs. Neostigmine was evaluated on Recovery time from administration to a train-of-four (TOF) ratio of ≥90% (MD -15.40, 95% CI -26.64 to -4.15, p=0.0073). Sugammadex significantly shortened recovery time to a TOF ratio ≥90% compared to neostigmine (MD -15.40; 95% CI -26.64 to -4.15; p=0.0073) and reduced the risk of postoperative residual curarization.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: